Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche's I/O TIGIT + Tecentriq combo effective .. BUT ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5194)
•••
Comment by Noteableon Mar 30, 2022 11:33am
164 Views
Post# 34559117

RE:Roche's I/O TIGIT + Tecentriq combo effective .. BUT ...

RE:Roche's I/O TIGIT + Tecentriq combo effective .. BUT ...
Interim data from Genentech (Roche)'s first randomized study of a candidate treatment for extensive-stage small cell lung cancer (ES-SCLC) failed to meet its co-primary endpoint in an unfortunate loss in the battle against the hard-to-treat disease.

 Key secondary endpoints were safety and OS and PFS in all participants.

Tiragolumab is an immune checkpoint inhibitor that selectively binds to TIGIT, an inhibitory immune checkpoint, suppressing the immune response to cancer. The drug has been observed to work as an immune amplifier and combining it with Tecentriq could help overcome immune suppression and restore immune response. Genentech said it will continue exploring potential therapies for this disease to help improve patient outcomes, particularly as the current standard of care also affects perfectly healthy cells.


https://www.biospace.com/article/genentech-s-es-sclc-drug-candidate-tiragolumab-fails-to-meet-key-endpoint/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities